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Abstract: Papilledema is considered a neuro-ophthalmic emergency because of its capacity 
to induce irreversible end-organ damage and the often grave nature of its precipitating fac-
tor. Even more concern is warranted when papilledema presents in a pediatric setting. After 
excluded the contributions of intracranial masses, congenital malformations, ischemic insults 
and acute infections, the investigation must focus on determining the contributions of other 
uncharacteristic causes of pediatric pseudotumor cerebri. Pediatric pseudotumor cerebri is a rare 
clinical entity which shares few commonalities to the adult condition in regards to its predicating 
factors or symptoms. Without adequate medical history questioning, funduscopic evaluation and 
ancillary testing, the possibility of an erroneous diagnosis is plausible. This case report aims to 
disclose the toxic role levothyroxine sodium tablets (Synthroid®, Abbott Laboratories, Abbott 
Park, IL, USA) played in inducing pseudotumor cerebri in a pediatric patient being treated for 
congenital hypothyroidism.
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Background
Pseudotumor cerebri (PTC) is a condition that classically presents with optic disc 
elevation and edema resulting from increased intracranial pressure in absence of 
hydrocephalus, space occupying lesion, or any other intracranial disease. Studies show 
that obese women in their childbearing years are most frequently affected with an 
incidence rate more than a hundred times that of the general population (90/100,000 
women vs 0.9–1.7/100,000 people) (Campos and Olitsky 1995). The symptom complex 
of a patient with PTC is variable but commonly includes nausea, emesis, amaurosis 
fugax, diplopia, tinnitus, retrobulbar pain, and postural headaches (Campos and Olitsky 
1995). Although there are few cases of pediatric PTC in literature, current reports sug-
gest that pediatric PTC symptoms are typically less severe as compared to adults and 
no sexual predilection or correlation with obesity has been shown to exist. Symptoms 
appear to parallel adult-like symptoms the older the child is at time of presentation 
(Raghaven et al 1997). Emotional irritability and somnolence are two key symptoms 
that appear to more commonly afﬂ  ict infants and younger children who suffer from 
pediatric PTC (Raghaven et al 1997).
In both the adult or pediatric presentations, preservation of vision and visual ﬁ  eld 
are principle concerns that must be addressed immediately. It has been shown that 
85% of the patients presenting with signs and symptoms of PTC possess a visual 
ﬁ  eld abnormality (Cincirpini et al 1999). In pediatric PTC cases, the degree of visual 
ﬁ  eld loss is between 13%–38% with 46% of these cases demonstrating an enlarged 
blind spot (Cincirpini et al 1999). Although the cause of pediatric PTC is often a 
mystery, the contributions of several secondary factors have surfaced including various Clinical Ophthalmology 2007:1(4) 546
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endocrine disorders and iatrogenic causes (Wilson and Baker 
2005) (Table 1). The following report illustrates the toxic 
contribution of oral levothyroxine therapy (Synthroid®, 
Abbott Laboratories, Abbott Park, IL, USA) employed for 
the treatment congenital hypothyroidism in precipitating a 
case of pediatric PTC.
Congenital hypothyroidism affects approximately 1 in 
every 4000 infants in the United States and is caused by an 
infant’s inability to produce an adequate level of thyroid 
hormone (Bourgeois and Varma 2005). Principal causes 
of this congenital deficiency include a malfunctioning 
thyroid gland, an iodine deﬁ  ciency, or defective thyroid 
metabolism. Because of the thyroid hormone’s critical role in 
promoting neuronal myelination for normal central nervous 
system development during the early postpartum period, 
supplemental therapy must be initiated early in a child’s life 
(Bourgeois and Varma 2005).
Levothyroxine sodium (Synthroid®, Abbott Laboratories, 
Abbott Park, IL, USA) is used as a replacement therapy 
in the setting of diminished or absent thyroid function 
due to primary thyroid gland dysfunction or secondary
etiologies such as autoimmune destruction, trauma, surgery, 
radio-ablation, drug-toxicity or infections. Synthroid® is 
a synthetic replacement for thyroxine (T4), the principal 
hormone that is synthesized and released by the thyroid 
gland. As a therapeutic agent, levothyroxine sodium has a 
narrow therapeutic range. If the fractions of levothyroxine 
sodium administered are sub-optimal, the desired reversal 
of the hypothyroid-state is not attained. Unfortunately, the 
main complication reported to arise in pediatric admin-
istration of levothyroxine sodium is usually the result of 
over-administration of the drug or an allergic reaction to the 
synthetic formulation (Bourgeois and Varma 2005). Adults 
with clinically-conﬁ  rmed thyroid dysfunction often require 
1.6 μg/kg of levothyroxine per day, whereas pediatric patients 
often require higher fractions, up to 4 μg/kg/day. Careful 
titration of the administered dosages of levothyroxine sodium 
is performed every 6 weeks after initiating therapy till the 
desire level of free T4 and TSH are attained. Regular assays 
are collected thereafter to avoid over- or under-medicating 
patients with thyroid dysfunction.
Although not life-threatening, negligence of the signs 
of hypothyroidism (fatigue, dry skin, cold intolerance, and 
weight gain) in a pediatric patient may have serious reper-
cussions later in life by engendering memory impairment, 
mental retardation, cardiac dysfunction and myxedema 
coma. Equally signiﬁ  cant is the fact that congenital or 
iatrogenically-induced states of hyperthyroidism can 
predispose a patient to early-onset osteoporosis and cardiac 
complications (atrial ﬁ  brillation, supraventricular arrhyth-
mias). In light of the significant clinical consequences 
associated with improper thyroid-replacement therapy, 
the pediatric dosing schedule of levothyroxine sodium is 
kept at the minimum dosage which yields normal, stable
thyroid function tests without noting tachycardia, palpita-
tions, tremors, agitation, hyperactivity, weight loss, fever 
or diaphoresis in the child (Bourgeois and Varma 2005). 
A standardized dosing regimen has been published to assist 
in the reduction of deleterious toxic sequelae (Bourgeois and 
Varma 2005) (Table 2). The neuro-ophthalmic complication
of levothyroxine-induced PTC has been reported in literature 
to arise with the initiation or during the course of therapy 
in a pediatric setting. The medical community at large must 
be alert to the signs and symptoms of this neuro-ophthalmic 
emergency that may be induced in response to toxic levels 
of levothyroxine sodium and be cognoscente of the fact it 
may arise in isolation of other more common indicators of 
iatrogenic-hyperthyroidism. Furthermore, clinicians should 
consider levothyroxine-induced PTC as a situation that war-
rants re-investigation or adjustment of the current levels of 
levothyroxine sodium replacement therapy.
Case report
An 11-year-old Caucasian female presented for a routine 
eye exam complaining of chronic headaches for the last 12 
months. She reported supra-nuchal, radiating pain that was 
rated as an “8” on a 10 point scale. These headaches were 
exacerbated during postural changes such as while tying 
her shoes. Nausea, vomiting, visual aura, amaurosis fugax, 
phonophobia, diplopia, tinnitus and an altered mental status 
were not reported. Medical history was remarkable for 
Table 1 Reported secondary causes of pseudotumor cerebri 
(Wilson and Baker 2002)
• Hypervitaminosis  A    • Immunizations
•  Retinoic acid   •  Infection/Inﬂ  ammation
•  Tetracylcines   •  Thyroid dysfunction (hypo- 
     and  hyper-)
• Nitrofurantoin  • Parathyroid  dysfunction  (hypo- 
     and  hyper-)
• Fluoroquinolones  • Adrenal  dysfunctions
• Lithium  • Hypocalcemia  in  vitamin  D
     deﬁ  ciency
•  Oral contraceptives  •  Addison’s disease
• Pregnancy    • Panhypopituitarism
•  Re-feeding and weight   •  Steroid use and withdrawl
   gain in nutritionally
   deprived children  •  LevothyroxineClinical Ophthalmology 2007:1(4) 547
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juvenile diabetes mellitus and congenital hypothyroidism. 
The patient’s mother noted that these diagnoses were 
assigned in infancy. Current medical therapy included insu-
lin NPH 100 units/ml s.c. bid (Novolin N®, Nov Nordisk 
Pharmaceuticals, Princeton, NJ, USA), and levothyroxine 
100 μg p.o. qd (Synthroid®, Abbott Laboratories, Abbott 
Park, IL, USA).
Visual acuities were recorded as 20/30 OD and 20/40 OS 
without correction. Pupils were equal, round with brisk, sym-
metrical responses to light; no afferent pupillary defect was 
noted. Versions were full, smooth, and accurate in all gazes. 
Color vision was normal with Ishihara pseudo-isochromatic 
plate testing. Cover test uncovered an 8 prism diopter 
esophoria at near and orthophoria at distance. Manifest 
refraction yielded a prescription of OD: −1.00 −0.25 × 105, 
OS: −0.50 −0.75 × 105 with a +1.00 add to attain 20/20 OU 
at all distances and eliminate her near phoria.
Anterior segment was grossly unremarkable. Goldmann 
applanation uncovered intraocular pressures of 16 mmHg 
OD, 16 mmHg OS. Blood pressure readings were recorded as 
128/84 mmHg. Funduscopic evaluation revealed bilaterally 
edematous, elevated and non-hemorrhagic optic nerves 
(Figure 1). Cup-to-disc ratio was approximated at 0.30 H/V 
OD, 0.30 H/V OS. Spontaneous venous pulsations were 
absent OU. The lenticular and vitreal media were clear. 
Peripheral eye grounds were clear, ﬂ  at and intact 360º OU.
Automated Humphrey® visual field testing (SITA-
Standard, 30-2, size III stimulus) results were deemed unre-
liable likely owing to the patient’s age; nevertheless mild 
bilateral blindspot enlargement was discernible.
Immediate referral to a pediatric neuro-ophthalmologist 
was initiated with a request for T-1 weighted MRI imag-
ing of the patient’s head/orbit and lumbar puncture 
studies including cerebrospinal ﬂ  uid (CSF) cultures and 
opening pressures. No space-occupying lesion, congenital 
aterio-venous malformations or hydrocephalus was detected 
during neuroimaging studies. Cerebral spinal ﬂ  uid cultures 
revealed the absence of infection or pleocytosis. Opening 
pressures were not recovered by attending physician at the 
time of the lumbar puncture.
After consulting with the patient’s endocrinologist, the 
patient’s neuro-ophthalmologist initiated acetazolamide 
250 mg bid p.o. (Diamox®, Lederle Laboratories, Pearl 
River, NY, USA) in place of modulating her current 
levothyroxine-therapy. Fortunately, the patient was afforded 
partial relief from her headache pain over the course of the 
next several weeks. Repeated automated perimetry testing 
has demonstrated stability in the pattern of bilateral blind-
spot enlargement. Six months after her initial presentation, 
funduscopic evaluation demonstrates an improved degree 
of optic nerve head elevation, but a persistent pattern of 
blindspot enlargement on visual ﬁ  eld testing.
Table 2 Recommended initial dosing schedule of levothyroxine 
for pediatric patients (Bourgeois and Varma 2005)
Age  Recommended dosage level
6 months  8–10 μg/kg/d PO or 25–50 μg/d PO
6–12 months  6–8 μg/kg/d PO or 50–75 μg/d PO
1–5 years  5–6 μg/kg/d PO or 75–100 μg/d PO
6–12 years  4–5 μg/kg/d PO or 100–150 μg/d PO
12 years  2–3 μg/kg/d PO or 150 μg/d PO
 IV/IM  = 50%–75% of PO dose
Figure 1 Funduscopic images of non-hemorrhagic, elevated, and edematous optic nerves noted in the right (1-A) and left (1-B) eyes of our patient. No spontaneous venous 
pulsations were detected at initial examination.
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for hypothyroidism. This child also reported concomitant 
symptoms of eye pain, tinnitus, nausea and vomiting. Only 
after titrating the levels of levothyroxine being administered 
to the patient (50 μg/day), did the patient’s symptoms resolve 
over the next few months despite persistent papilledema on a 
subsequent funduscopic examination. Neuroimaging studies 
and lumbar puncture conﬁ  rmed a diagnosis of pseudotumor 
cerebri owing to toxic levothyroxine levels (Campos and 
Olitsky 1995). McVie (1984) described a 13 year old girl 
whose severe headaches and concurrent papilledema which 
began after only 3 days of starting levothyroxine therapy 
resolved once levothyroxine therapy was discontinued and 
subsequently re-initiated at a level of 50 μg/kg.
Although standardized dosing regimens have been 
proposed, no clear consensus exists for determining a safe 
initial dosing schedule for pediatric patients suffering from 
congenital hypothyroidism to prevent systemic complication 
from the drug itself. (Table 2) The current reported cases 
infer that the toxicities arising from levothyroxine therapy 
arise from improper initial dosing selection or dosages that 
over-shoot the therapeutic window. This in turn suggests 
that the toxic effects are independent of cumulative dosing 
of this synthetic hormone. Selva et al (2002) looked at initial 
dosing schedules of patients with congenital hypothyroidism 
and suggested titration of the initial dosage is essential to 
limit levothyroxine’s harmful effects on neurologic develop-
ment. They concluded that initial dosing of ∼12–15 μg/kg 
raised thyroxine levels to target levels within 3 days, 
normalized thyroid function tests within 2 weeks of initiat-
ing therapy and presented few deleterious complications in 
the majority of patients. Because of the variability in patient 
pharmacokinetic responses to any medication, it is advisable 
that all children be monitored closely during the initiation 
phase of levothyroxine therapy to limit the occurrence of 
neurological side effects.
In literature, few authors propose a deﬁ  nitive treatment 
paradigm or clinically superior therapy to resolve pediatric 
cases of PTC. Two studies suggest that initial modulation of 
the level of thyroid replacement hormone is often sufﬁ  cient 
to promote the resolution of the signs and symptoms of 
PTC (Van Dop et al 1983; McVie 1984). Other reports 
infer that no change to the patient’s thyroid replacement 
regimen is needed, since the signs and symptoms of PTC 
have the capacity to self-resolve (Prendes and McLean 
1978). However, if prompt resolution of PTC is warranted, 
medical intervention using oral carbonic anhydrase inhibitors 
or immunosuppressive therapy have shown to be effective 
at reducing CSF production and reversing the signs of 
Patient was counseled as to the beneﬁ  t of a second 
opinion from another pediatric neuro-ophthalmologist and 
endocrinologist to ensure that visual morbidity would be 
minimized. Patient denied additional intervention and was 
eventually lost to follow-up.
Discussion
Pediatric pseudotumor cerebri (PTC) is a rarely reported 
phenomenon in neuro-ophthalmology literature. Never-
theless, awareness and quick intervention are essential to 
prevent unnecessary vision loss from this reversible clinical 
entity. Diagnosing pediatric PTC is challenging since chil-
dren and young adults exhibit a clinical presentation that is 
unlike that reported in adults manifesting this condition. In 
considering this diagnosis, the astute clinician must employ 
a step-wise approach that is in keeping with the criteria 
listed in the modiﬁ  ed Dandy Criteria to ensure absolute 
certainty in their diagnosis (Smith 1985; Langford 2002) 
(Table 3). In-depth probing of a patient’s medical, social 
and family history may help to uncover the contributions of 
a secondary factor in manifesting PTC (Wilson and Baker 
2005) (Table 1). When no identiﬁ  able cause can be found, 
it is appropriate to label this clinical entity as idiopathic 
intra-cranial hypertension.
This case report illustrates how medical history question-
ing provided the basis for determining the cause of the PTC to 
be a toxic level of levothyroxine. A review of current literature 
suggests that there are at least half a dozen reports outlining 
the role levothyroxine played in inducing secondary PTC in 
a child or young adult (Van Doop et al 1983; McVie 1984; 
Huseman and Torkelson 1985; Rohn 1985; Campos and 
Olitsky 1995; Rovet and Ehrlich 1995; Raghaven et al 1997; 
Williams 1997; Langford 2002; Selva et al 2002). Raghavan 
et al (1997) described a 5 month old infant who developed PTC 
shortly after initiation of levothyroxine (50 μg/kg) therapy. 
Campos and Olitsky (1995) described a case of a 7½ year old 
patient who developed severe, widespread headaches after 
1 week of commencing levothyroxine therapy (75 μg p.o. qd) 
Table 3 Modiﬁ  ed dandy criteria for diagnosis of pseudotumor 
cerebri (Smith 1985; Langford 2002)
•  Signs and symptoms of elevated intra-cranial pressure
•  No localizing neurologic signs except CN VI palsy
•  Normal neuro-anatomy and cerebral spinal ﬂ  uid
• Intra-cranial  pressure  200 mmHg (in non-obese 
   patients) or 250 mmHg (in obese patients) 
• No  2° cause of elevated intra-cranial pressure
•  Patient is awake & alertClinical Ophthalmology 2007:1(4) 549
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papilledema in other clinical scenarios (Baker et al 1985). 
Surgical intervention should only be considered if medical 
therapy fails to achieve an appropriate endpoint, headaches 
persist, or progressive vision loss ensues. Optic nerve 
sheath fenestration (ONSF) is a neuro-ophthalmic procedure 
designed to create an alternative outﬂ  ow channel for the CSF 
which encircles the intra-orbital portion of the optic nerve. 
It is a procedure that is limited almost exclusively to the 
treatment of PTC and has been shown to manifest signiﬁ  cant 
beneﬁ  ts along with an adequate safety proﬁ  les in children 
suffering from pediatric PTC (Lee et al 1998; Thuente and 
Buckley 2005). Lee et al (1998) reported on the effects of 
optic nerve sheath fenestration (ONSF) in 12 children who 
were previously unresponsive to typical pharmacological 
intervention. They noted that 66% of patients’ showed 
improvements in visual acuity, while 17% showed stability 
and the remaining 17% experienced a worsening in their level 
of acuity. A similar breakdown was noted with regards to the 
patient’s peripheral vision, with 2/3 of pediatric PTC patients’ 
experiencing an improvement or stability in their side-vision; 
while 1/3 suffered from continued deterioration following 
ONSF. In a follow-up investigation by Thuente and Buckley 
(2005), the outcome of ONSF in 17 eyes (12 children) that 
were previously unresponsive to medical therapy was once 
again examined. Seven of the twelve children only required 
unilateral ONSF to attain an improvement in the degree of 
papilledema in the contralateral eye. For those who mani-
fested more advanced papilledema at presentation, bilateral 
ONSF was performed within 3–4 months of this initial sur-
gical intervention. Similarly to Lee and colleagues (1998) 
initial investigation, the level of visual acuity and degree of 
visual ﬁ  eld attenuation was more likely to be improved or 
stabilized following ONSF; these ﬁ  ndings were noted to most 
often arise in conjunction with a regression in the degree of 
papilledema. As such, the authors surmised that ONSF is a 
safe and effective adjunctive therapy for pediatric cases of 
medically-unresponsive PTC.
Conclusion
Pre-cautionary measures should always be taken with 
pediatric patients receiving levothyroxine therapy for 
congenital hypothyroidism. Despite its widespread use 
and relatively benign safety proﬁ  le, levothyroxine main-
tains a capacity to induce visually devastating sequelae 
in young patients. We advise considering levothyroxine 
as a potential cause of secondary PTC especially if the 
signs and symptoms arise shortly after commencing 
therapy or arise in a pediatric setting. Despite the lack 
of neuro-ophthalmic literature citing the contributions of 
presumed levothyroxine-induced pediatric PTC, awareness 
of this rare clinical occurrence is vital to ensure prompt 
diagnosis and appropriate management.
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